Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron for pain after ureteral stent placement
NCT02462837Phase 2Terminated
- Sponsor
- Southern Illinois University
- Start
- May 2015
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mirabegron in ureteral stent-related symptoms (USRS) (2 arms), sponsored by Southern Illinois University. Primary endpoints: Incontinence Symptom Severity Index at 2 weeks, Number of Micturitions Per 24 Hours at 2 weeks and 1 more. Started May 2015; status: terminated.
02
Drugs
mirabegron
03
Conditions
ureteral stent-related symptoms (USRS)
Beyond the preview
Go deeper on NCT02462837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462837.